Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder

Hasan Khoonsari 1 , Mohammad Bagher Oghazian 1 , Mona Kargar 2 , Mahdiyeh Moin 3 , Hossein Khalili 1 , Abbas Alimadadi 4 , Hassan Torkamandi 5 and Padideh Ghaeli 6 , *
Authors Information
1 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2 Research Center for Rational Use of Drugs, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Psychiatry, Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 University of Applied Science and Technology, Tehran, IR Iran
5 Pharmaceutical Care Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
6 Psychiatry and Psychology Research Center, Faculty of Pharmacy, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: June 28, 2015, 9 (2)
  • Published Online: June 23, 2015
  • Article Type: Original Article
  • Received: February 1, 2014
  • Revised: November 6, 2014
  • Accepted: November 28, 2014
  • DOI: 10.17795/ijpbs230

To Cite: Khoonsari H, Oghazian M B, Kargar M, Moin M, Khalili H, et al. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder, Iran J Psychiatry Behav Sci. 2015 ; 9(2):-. doi: 10.17795/ijpbs230.

Copyright © 2015, Mazandaran University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Kara S, Yazici KM, Gulec C, Unsal I. Mixed anxiety-depressive disorder and major depressive disorder: comparison of the severity of illness and biological variables. Psychiatry Res. 1971; 94(1): 59-66[PubMed]
  • 2. Balestrieri M, Isola M, Quartaroli M, Roncolato M, Bellantuono C. Assessing mixed anxiety-depressive disorder. A national primary care survey. Psychiatry Res. 2010; 176(2-3): 197-201[DOI][PubMed]
  • 3. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2010;
  • 4. Spijker J, Batelaan N, de Graaf R, Cuijpers P. Who is MADD? Mixed anxiety depressive disorder in the general population. J Affect Disord. 2010; 121(1-2): 180-3[DOI][PubMed]
  • 5. Carrasco JL, Diaz-Marsa M, Saiz-Ruiz J. Sertraline in the treatment of mixed anxiety and depression disorder. J Affect Disord. 2000; 59(1): 67-9[PubMed]
  • 6. Chen Y, Kelton CM, Jing Y, Guo JJ, Li X, Patel NC. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Social Adm Pharm. 2008; 4(3): 244-57[DOI][PubMed]
  • 7. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008; 149(10): 734-50[PubMed]
  • 8. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(1): 85-102[PubMed]
  • 9. Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Tazuma S. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole. Dig Liver Dis. 2006; 38(8): 554-9[DOI][PubMed]
  • 10. Valles JA, Barreiro M, Cereza G, Ferro JJ, Martinez MJ, Escriba JM, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy. 2003; 65(3): 269-75[PubMed]
  • 11. Chua GN, Hassali MA, Shafie AA, Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy. 2010; 95(2-3): 229-35[DOI][PubMed]
  • 12. Simoens S. Developing competitive and sustainable Polish generic medicines market. Croat Med J. 2009; 50(5): 440-8[PubMed]
  • 13. Citalopram.
  • 14. Management of Drugs at Health Centre Level - Training Manual. 2004;
  • 15. Citalopram. 2012;
  • 16. Diagnostic and statistical manual of mental disorders. 2000;
  • 17. Finley PR, Lee KC. Koda-Kimble and Young's Applied Therapeutics: The clinical Use of Drugs. 2013; : 1949-82
  • 18. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; 25(11): 2875-90[PubMed]
  • 19. Trade, foreign policy, diplomacy and health: Generic Drugs. 2011;
  • 20. Generic Drugs: Questions and Answers.
  • 21. Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS. Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review. Parkinsonism Relat Disord. 2011; 17(5): 308-12[DOI][PubMed]
  • 22. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004; 5(6): 995-8[DOI][PubMed]
  • 23. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther. 2001; 23(10): 1720-31[PubMed]
  • 24. Bautista RE, Gonzales W, Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res. 2011; 95(1-2): 158-67[DOI][PubMed]
  • 25. Yu BP, Chong YS, Maguire GA. Is generic fluoxetine effective? J Affect Disord. 2004; 81(2): 185-6[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments